lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 3, 2026

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer

View original at finance.yahoo.com
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer For Immediate Release Chicago, IL – March 3, 2026 – Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ, Sanofi SNY and Bayer BAYRY…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    80% confidence
  • J&J expects sales growth in both segments (Innovative Medicine and MedTech) to be higher in 2026

    80% confidence
  • Lilly expects to launch orforglipron for obesity in the United States during the second quarter of 2026 and in most international markets during 2027

    80% confidence
  • The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025

    80% confidence
  • President Trump has threatened to impose a 100% tariff on pharmaceutical imports unless a company builds pharmaceutical plants in the United States

    80% confidence
  • Innovation is at its peak with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention

    80% confidence
  • Lilly expects its new drugs, Mounjaro, Zepbound, Ebglyss, Jaypirca, Inluriyo, Kisunla and Omvoh to drive sales growth in 2026

    80% confidence
  • Despite the headwinds, the industry's focus on innovation and positive pipeline/regulatory developments signals a favorable long-term outlook

    80% confidence
  • Overall, large drugmakers have several robust revenue streams and are mostly profitable companies, making them safe havens for long-term investment

    80% confidence
  • M&A activity has shot up in 2026 after a lull in the past couple of years

    80% confidence
  • Among the large drugmakers, Eli Lilly, Johnson & Johnson, Sanofi and Bayer are worth retaining in one's portfolio

    80% confidence
  • The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank #172, which places it in the bottom 29% of 243 Zacks industries

    80% confidence
  • Sales of late-life cycle products like Trulicity, Taltz and Verzenio are expected to be flat to down in 2026

    80% confidence
  • J&J looks optimistic for continued strong momentum in 2026, with a target to generate around $100 billion in revenues in the year

    80% confidence

Data points we hold from this source

Sanofi · eps4.97 USD
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer: Source | Via News | fr.via.news